Opinion|Videos|July 1, 2024
Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
Wenxin (Vincent) Xu, MD, reviews recent analyses from the CLEAR study, which evaluated the combination of lenvatinib and pembrolizumab as a frontline treatment for advanced renal cell carcinoma (RCC).
Advertisement
Episodes in this series
- Please discuss recent analyses from the CLEAR study, evaluating lenvatinib + pembro in frontline advanced RCC.
- Efficacy by baseline tumor size (Grunwald, et al. ASCO GU 2024. Abstract 364)
- Biomarker analysis (Motzer et al. ASCO 2024 Abstract 4504)
- Network meta-analysis– len + pembro vs other 1L treatments in advanced RCC (Grunwald, et al. ASCO GU 2024. Abstract 482)
Advertisement
Related to this article
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
2
Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer
3
Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia
4
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
5